In recent years, the life sciences industry has recognized the need to embrace patient centricity and deliver value beyond return on investment. Yet the industry has struggled to measure the true impact for patients. Instead, organizations more regularly measure activities as a proxy for impact, leaving a gap in understanding of where and how they have influenced change. We aim to change that.
ZS’s long-term ambition is to develop an all-encompassing, universal metric that can be used across therapeutic areas and companies to index, assess and compare the impact of patient-focused investments on outcomes. As a first step to developing this measure, ZS developed an approach to Patient Outcomes Impact (POI™) measurement. This approach helps organizations identify metrics that are important to business and patients alike. It also outlines a robust analytical approach that helps organizations attribute impact to their patient-focused activities.
To demonstrate the feasibility of applying the POI metrics framework to life sciences investments, ZS performed a proof-of-concept study to understand how four unbranded disease awareness campaigns in the cardiovascular space influenced diagnosis, diagnostic delay, treatment and treatment delay. The analysis uncovers significant patient-focused impact created by each of the campaigns and identifies impact gaps where additional efforts are required to further drive improved outcomes for all.
Add insights to your inbox
We’ll send you content you’ll want to read – and put to use.
